4-氟-2-苯基氨基-苯甲酸 | 365-54-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-2-苯基氨基-苯甲酸
• 英文名称: 4-fluoro-2-(phenylamino)benzoic acid
• 英文别名: 2-anilino-4-fluorobenzoic acid
• CAS: 365-54-8
• 化学式: C₁₃H₁₀FNO₂
• 分子量: 231.226
• InChiKey: DQDYIKGGALFGSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  4-氟-2-苯基氨基-苯甲酸 在 三氯氧磷 作用下， 生成 9-chloro-3-fluoroacridine
  参考文献：
  名称：

  145.对氟取代的5-氨基ac啶及相关化合物的性质的研究。第一部分：一氟-5-氨基ac啶

  摘要：

  DOI：

  10.1039/jr9470000759
• 作为产物：
  描述：

  4-氟-2-硝基苯甲酸 在 铁粉 、 铜 、 potassium carbonate 、 氯化铵 、 potassium iodide 作用下， 以 乙醇 、 水 为溶剂， 生成 4-氟-2-苯基氨基-苯甲酸
  参考文献：
  名称：

  Discovery of a novel series of 4-quinolone JNK inhibitors

  摘要：

  A novel series of highly selective JNK inhibitors based on the 4-quinolone scaffold was designed and synthesized. Structure based drug design was utilized to guide the compound design as well as improvements in the physicochemical properties of the series. Compound (13c) has an IC50 of 62/170 nM for JNK1/2, excellent kinase selectivity and impressive efficacy in a rodent asthma model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.10.066

文献信息

• Redox-neutral decarboxylative photocyclization of anthranilic acids
  作者：Huawen Huang、Kun Deng、Guo-Jun Deng

  DOI：10.1039/d0gc02789h

  日期：——

  photoredox neutral system has been found to efficiently enable intramolecular decarboxylative cyclization of anthranilic acids. This facile protocol provides an alternative method for the synthesis of carbazoles. Mechanistic studies reveal a key photoinduced 6π-electrocyclization process and formic acid was released as the sole byproduct.

  已经发现，温和的，无金属，无催化剂和无氧化剂的光氧化还原中性体系可以有效地实现邻氨基苯甲酸的分子内脱羧环化。该简便方案为咔唑的合成提供了另一种方法。机理研究揭示了关键的光诱导的6π-电环化过程，甲酸是唯一的副产物。
• Dihydroquinone and dihydronaphthridine inhibitors of JNK
  申请人：Abbot Sarah C.

  公开号：US20080287458A1

  公开（公告）日：2008-11-20

  Compounds of formula I are effective modulators of JNK: wherein X is CR 11 or N; Y is —C(O)R 3 , 5-membered heteroaryl, or 5-membered heterocyclyl; Z is phenyl, cycloalkyl, heterocyclyl or heteroaryl, and is substituted with R 1 and R 2 ; R 1 and R 2 are each independently H, halo, CN, lower alkyl, or —Y 1 —Y 2 —Y 3 —R 8 , or R 1 and R 2 together form —O(CH 2 ) n O—, where n is 1 or 2; Y 1 is —O—, —C(O)—, —C(O)O—, —C(O)NR 9 —, —NR 9 C(O)—, —S—, —SO 2 —, or a bond; Y 2 is cycloalkylene, heterocycloalkylene, lower alkylene or a bond; Y 3 is —O—, —C(O)—, —C(O)O—, —C(O)NR 9 —, —NR 9 C(O)—, —SO 2 —, or a bond; R 8 is H, lower alkyl, lower alkoxy, cycloalkyl, heterocycloalkyl, or —NR 9 R 10 , wherein R 8 other than H is optionally substituted with lower alkyl, halo, —CF 3 , or —OH; R 9 and R 10 are each independently H or lower alkyl; R 3 is OH, lower alkyl, lower alkoxy, (lower alkoxy)-lower alkoxy, or —NR 9 R 10 ; R 4 is lower alkyl, phenyl, heterocyclyl, cycloalkyl, heterocycloalkyl, or heteroaryl, and is optionally substituted with lower alkyl, hydroxy, lower alkoxy, halo, nitro, amino, cyano, or halo-lower alkyl; R 5 and R 6 are each independently H, halo, cyano, lower alkyl, —CF 3 , lower alkoxy, —OCHF 2 , —NO 2 , or —NR 9 R 10 ; R 7 is H, F, Cl, methyl, or OH; R 11 is H, lower alkyl, lower cycloalkyl, or phenyl; or a pharmaceutically acceptable salt thereof.

  式I的化合物是JNK的有效调节剂： 其中 X为CR11或N； Y为—C(O)R3，5-成员杂芳基，或5-成员杂环烷基； Z为苯基，环烷基，杂环烷基或杂芳基，并且被R1和R2取代； R1和R2各自独立地为H，卤素，CN，较低烷基，或—Y1—Y2—Y3—R8，或R1和R2一起形成—O(CH2)nO—，其中n为1或2； Y1为—O—，—C(O)—，—C(O)O—，—C(O)NR9—，—NR9C(O)—，—S—，—SO2—，或键； Y2为环烷亚烷基，杂环烷亚烷基，较低烷基亚烷基或键； Y3为—O—，—C(O)—，—C(O)O—，—C(O)NR9—，—NR9C(O)—，—SO2—，或键； R8为H，较低烷基，较低烷氧基，环烷基，杂环烷基，或—NR9R10，其中R8除H外可选择地被较低烷基，卤素，—CF3，或—OH取代； R9和R10各自独立地为H或较低烷基； R3为OH，较低烷基，较低烷氧基，(较低烷氧基)-较低烷氧基，或—NR9R10； R4为较低烷基，苯基，杂环烷基，环烷基，杂环烷基，或杂芳基，并且可选择地被较低烷基，羟基，较低烷氧基，卤素，硝基，氨基，氰基，或卤素较低烷基取代； R5和R6各自独立地为H，卤素，氰基，较低烷基，—CF3，较低烷氧基，—OCHF2，—NO2，或—NR9R10； R7为H，F，Cl，甲基，或OH； R11为H，较低烷基，较低环烷基，或苯基； 或其药用可接受盐。
• Light‐Driven Intramolecular C−N Cross‐Coupling via a Long‐Lived Photoactive Photoisomer Complex
  作者：Dong Jing、Cong Lu、Zhuo Chen、Songyang Jin、Lijuan Xie、Ziyi Meng、Zhishan Su、Ke Zheng

  DOI：10.1002/anie.201906112

  日期：2019.10.7

  Reported herein is a visible-light-driven intramolecular C-N cross-coupling reaction under mild reaction conditions (metal- and photocatalyst-free, at room temperature) via a long-lived photoactive photoisomer complex. This strategy was used to rapidly prepare the N-substituted polycyclic quinazolinone derivatives with a broad substrate scope (>50 examples) and further exploited to synthesize the natural

  本文报道的是可见光驱动的分子内CN交叉偶联反应，该反应在温和的反应条件下（室温下无金属和光催化剂）通过长寿命的光敏光异构体络合物进行。该策略用于快速制备具有广泛的底物范围（> 50个实例）的N-取代的多环喹唑啉酮衍生物，并进一步用于合成天然产物色胺酮，鲁塔卡品及其类似物。克级合成和太阳驱动转化的成功以及有希望的抑制肿瘤的生物活性证明了该策略在实际应用中的潜力。机理研究，包括对照实验，DFT计算，紫外可见光谱，EPR和关键中间体的X射线单晶结构，
• [EN] AMINOMETHYL QUINOLONE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOMÉTHYL-QUINOLONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013007676A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula (I): wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  这项发明涉及JNK抑制剂及相应的用于抑制JNK和治疗JNK介导的疾病的方法、配方和组合物。该申请披露了JNK抑制剂，如下所述的化学式(I)：其中变量如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。还披露了用于抑制JNK和治疗JNK介导的疾病等的方法和配方，以及用于制备上述化合物和相应组合物的过程。
• Tricyclic heterocyclic derivatives
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0471516A1

  公开（公告）日：1992-02-19

  The invention relates to tricyclic heterocyclic derivatives, or pharmaceutically-acceptable salts or in vivo hydrolysable esters thereof, which possess anti-cancer activity. The invention also relates to processes for the manufacture of said tricyclic heterocyclic derivatives, to novel pharmaceutical compositions containing them and to the use of said tricyclic heterocyclic derivatives in the manufacture of a medicament for the production of an anti-cancer effect. The invention provides an optionally substituted tricyclic heterocyclic derivative of the formula I wherein A together with the adjacent vinylene group of the 4-oxo-1,4-dihydropyrid-1-yl ring completes a benzene or pyridine ring;    R¹ and R², which may be the same or different, each is (1-4C)alkyl or (1-4C)alkoxy;    and R³ is hydrogen, (1-4C)alkyl or (1-4C)alkoxy;    or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.

  该发明涉及三环杂环衍生物，或其药用盐或体内可水解酯，具有抗癌活性。该发明还涉及制备所述三环杂环衍生物的方法，含有它们的新型药物组合物以及利用所述三环杂环衍生物制造抗癌药物以产生抗癌效果的用途。该发明提供了公式I的可选择取代的三环杂环衍生物，其中A与4-氧代-1,4-二氢吡啶-1-基环的相邻乙烯基团共同形成苯环或吡啶环；R¹和R²，可以相同也可以不同，分别是(1-4C)烷基或(1-4C)烷氧基；R³是氢，(1-4C)烷基或(1-4C)烷氧基；或其药用盐或体内可水解酯。